Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease ...
Mirum Pharmaceuticals, Inc. today reported financial results for the third quarter 2025 and provided a business update. "Mirum is well positioned heading into 2026 with strong commercial momentum and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback